ES486349A1 - Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas - Google Patents

Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas

Info

Publication number
ES486349A1
ES486349A1 ES486349A ES486349A ES486349A1 ES 486349 A1 ES486349 A1 ES 486349A1 ES 486349 A ES486349 A ES 486349A ES 486349 A ES486349 A ES 486349A ES 486349 A1 ES486349 A1 ES 486349A1
Authority
ES
Spain
Prior art keywords
hydrogen
carbon atoms
present
aminopyrimidines
substituted aminopyrimidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES486349A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2849537A external-priority patent/DE2849537C2/de
Priority claimed from DE19792937023 external-priority patent/DE2937023A1/de
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of ES486349A1 publication Critical patent/ES486349A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento para la preparación de 5-(2-imidazolin-2-il)- aminopirimidinas substituidas, de la fórmula general (I) **(Fórmula)** en la que R1, R2 y R3, que pueden ser iguales o diferentes, significan un átomo de hidrógeno o de halógeno, un grupo de alcoxilo, alquiltio o alquilo con 1 a 4 átomos de carbono o un grupo de cicloalquilo con 3 a 5 átomos de carbono, y R4 significa un átomo de hidrógeno o un grupo de acilo alifático o aromático, así como sus sales de adición de ácido compatibles fisiológicamente.
ES486349A 1978-11-15 1979-11-14 Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas Expired ES486349A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2849537A DE2849537C2 (de) 1978-11-15 1978-11-15 Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE19792937023 DE2937023A1 (de) 1979-09-13 1979-09-13 Neue substituierte 5-(2-imidazolin-2-yl)-aminopyrimidine und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
ES486349A1 true ES486349A1 (es) 1980-06-16

Family

ID=25776489

Family Applications (1)

Application Number Title Priority Date Filing Date
ES486349A Expired ES486349A1 (es) 1978-11-15 1979-11-14 Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas

Country Status (12)

Country Link
US (1) US4323570A (es)
AT (1) AT374197B (es)
AU (1) AU541305B1 (es)
CA (1) CA1138454A (es)
CH (1) CH642965A5 (es)
DK (1) DK150142C (es)
ES (1) ES486349A1 (es)
FR (1) FR2441625A1 (es)
GB (1) GB2039275B (es)
IT (1) IT1127225B (es)
NL (2) NL190553C (es)
SE (1) SE440079B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2146986B (en) * 1983-09-23 1987-06-17 Lilly Co Eli Process for preparing 5-substituted pyrimidines
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
US5977121A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Use of moxonidine for the treatment of atherosclerosis
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
CA2256720A1 (en) * 1996-06-06 1997-12-11 John Leeper Mcnay Jr. Formulation and method for treating congestive heart failure
CA2229123A1 (en) * 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
CA2269971A1 (en) * 1997-09-03 1999-03-11 Trent Lee Abraham Pyrimidine derivatives
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
WO2004000312A2 (de) * 2002-06-19 2003-12-31 Solvay Pharmaceuticals Gmbh Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
KR20080090546A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Ｃｎｓ 장애 치료용 2-이미다졸의 용도
EP1894926A1 (en) * 2006-06-26 2008-03-05 Chemagis Ltd. Polymorphs of moxonidine and processes for preparation therefor
ES2369113T3 (es) 2006-06-26 2011-11-25 Chemagis Ltd. Procedimiento mejorado para producir moxonidina.
ES2315967T3 (es) * 2006-06-26 2009-04-01 Chemagis Ltd. Nuevo procedimiento de purificacion de moxonidina.
WO2008020425A1 (en) * 2006-08-17 2008-02-21 Chemagis Ltd. Crystalline moxonidine comprising single tautomer and preparation process therefor
ATE487712T1 (de) * 2006-08-31 2010-11-15 Chemagis Ltd Verwendung der monoxidinssalze zur reinigung von monoxidin
WO2008046757A1 (en) * 2006-10-19 2008-04-24 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
DE602007005671D1 (de) * 2006-10-19 2010-05-12 Hoffmann La Roche Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren
KR101176700B1 (ko) * 2006-11-02 2012-08-23 에프. 호프만-라 로슈 아게 미량 아민 결합된 수용체의 조절자로서 치환된 2-이미다졸
JP2010510184A (ja) * 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
WO2008073125A1 (en) * 2006-12-12 2008-06-19 Chemagis Ltd. Moxonidine analogs, preparation processes and uses therefor
AU2007332641A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
NZ578260A (en) * 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
JP5130305B2 (ja) * 2007-02-15 2013-01-30 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしての２−アミノオキサゾリン
EP2173720A2 (en) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazolines having a good affinity to the trace amine associated receptors (taars)
EP2173719A1 (en) * 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazolines and their use as antidepressants
JP2010534701A (ja) * 2007-07-27 2010-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒリガンドとしての２−アゼチジンメタンアミン及び２−ピロリジンメタンアミン
KR20100039429A (ko) * 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 Ｃｎｓ 질환의 치료를 위한 벤즈아미드 유도체의 용도
JP5341084B2 (ja) * 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
AU2009273324A1 (en) * 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
EP2586779A1 (en) 2011-10-24 2013-05-01 Hetero Research Foundation Process for the preparation of moxonidine
DE102012215896A1 (de) * 2012-09-07 2014-03-13 Wörwag Pharma GmbH & Co.KG Moxonidinsynthese mit Hilfe organischer Basen
ES2608004T3 (es) 2012-12-03 2017-04-05 WÖRWAG PHARMA GmbH & Co. KG Método mediante catálisis por transferencia de fase
EP2765131B1 (en) 2013-02-08 2016-11-23 Arevipharma GmbH Process for the production of Moxonidine
WO2014140034A1 (en) * 2013-03-14 2014-09-18 Farmak, A.S. Improved process for the manufacture of moxonidine
EP2829540A1 (en) 2013-07-26 2015-01-28 Abbott Healthcare Products B.V. Synthesis of substituted aminopyridines
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体
GB202103400D0 (en) * 2021-03-11 2021-04-28 3Z Ehf Novel treatments
US20240002369A1 (en) 2020-11-12 2024-01-04 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines
GB1319840A (en) * 1970-08-27 1973-06-13 Beecham Group Ltd Substituted 5-amino imidazoles
BE795636A (fr) * 1972-02-19 1973-08-20 Schering Ag Nitroimidazolylpyrimidines, et leur procede de preparation
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
DE2220906A1 (de) * 1972-04-28 1973-11-15 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline-(2), deren saeureadditionssalze sowie verfahren zu deren herstellung
BE503170A (es) * 1975-09-02

Also Published As

Publication number Publication date
GB2039275A (en) 1980-08-06
FR2441625A1 (fr) 1980-06-13
CH642965A5 (de) 1984-05-15
SE7909392L (sv) 1980-05-16
NL940011I2 (nl) 1998-05-06
NL7908192A (nl) 1980-05-19
NL190553B (nl) 1993-11-16
AT374197B (de) 1984-03-26
SE440079B (sv) 1985-07-15
IT7927284A0 (it) 1979-11-14
DK150142B (da) 1986-12-15
US4323570A (en) 1982-04-06
DK481879A (da) 1980-05-16
ATA727079A (de) 1983-08-15
DK150142C (da) 1987-06-01
NL190553C (nl) 1994-04-18
AU541305B1 (en) 1985-01-03
CA1138454A (en) 1982-12-28
GB2039275B (en) 1982-11-17
IT1127225B (it) 1986-05-21
FR2441625B1 (es) 1981-12-31
NL940011I1 (nl) 1994-08-01

Similar Documents

Publication Publication Date Title
ES486349A1 (es) Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas
AU589795B2 (en) New 5-alkoxy-2,4-diamino-alkyl benzols, and hair tinting means using them
DE3271269D1 (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
DE3368053D1 (en) Substituated 1-hydroxy-ethyl-triazolyl derivatives
ES8800571A1 (es) Procedimiento para preparar un derivado de 1,3-oxazolidina-2-ona.
ZA816259B (en) 2-(1,4-benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
GB2115815B (en) Benzothiazoline compounds
AU576887B2 (en) 1,6-naphthyridine derivatives
IE780778L (en) 3-pyridazinones.
AU539870B2 (en) 2-phenylamino-imidazolines-(2)
NO822828L (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme 1-fenylindazol-3-on-forbindelser og deres salter
NO872874L (no) Amid-derivater.
ATE144900T1 (de) Verwendung von xanthinderivaten gegen magengeschwüre
ES8400420A1 (es) "procedimiento para la fabricacion de derivados n- susbtituidos de la tetrahidroisftalimida".
HUT53890A (en) Fungicides comprising o-(1,2,4-triazol-1-yl)-o-phenylacetate derivatives as active ingredient and process for producing the active ingredients
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.